After an avalanche of earnings updates, we turn to our annual Income Majors special report and dive into two prominent FTSE 100 dividend stocks. First up is insurer Legal & General; pressure has been mounting on the company as it grapples with a more competitive pensions market. Christopher Akers explains the CEO’s buyback plan, its yield and what it means for investors.

We then move to GSK, once known as GlaxoSmithKline, which faces a tricky balancing act between dividends and developing new drugs. The pharma giant has been spending heavily on R&D – a staggering £18bn this year alone to build its oncology pipeline. Julian Hofmann has the details.

Finally, we cast our ears to Hill & Smith’s growth across the pond. The steel products company now generates two-thirds of its revenue from the US and has even switched its currency from sterling to dollars. Michael Fahy discusses what’s going on at the growing business.

Timestamps:

00:00 Intro

03:22 Legal & General

10:42 GSK

18:57 Hill & Smith

Listen to more podcasts from Investors’ Chronicle on Apple, Spotify and YouTube

Investors' Chronicle has supported private investors in the UK for over 160 years by highlighting rewarding investment opportunities.

Investors' Chronicle is a service by the Financial Times.

Hosted on Acast. See acast.com/privacy for more information.

Legal & General, infrastructure stocks and GSK:Companies and Markets Show

Investors' Chronicle

Legal & General, infrastructure stocks and GSK:Companies and Markets Show